News
Kymab new therapeutic antibody for autoimmune diseases shows potential for improvement in post-transplant survival
Kymab Group Limited (“Kymab”), a leading monoclonal antibody biopharmaceutical group, announces today remarkable early stage results of its new antibody treatment, KY1005, which showed an improvement in post-transplant survival in an animal model of acute graft-versus-host-disease (GvHD), a common and potentially deadly complication of bone marrow transplants.